|
FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US7034007B1
(en)
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
|
US6825174B2
(en)
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US7087713B2
(en)
|
2000-02-25 |
2006-08-08 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
US6238921B1
(en)
*
|
1998-03-26 |
2001-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human mdm2 expression
|
|
AU760795B2
(en)
*
|
1998-05-14 |
2003-05-22 |
Coley Pharmaceutical Gmbh |
Methods for regulating hematopoiesis using CpG-oligonucleotides
|
|
AU5337499A
(en)
*
|
1998-08-03 |
2000-03-06 |
East Carolina University |
Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
|
|
PT1832657E
(pt)
*
|
1998-09-09 |
2013-01-08 |
Genzyme Corp |
Metilação de vectores plasmídicos
|
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US6214986B1
(en)
*
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
US6172216B1
(en)
*
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
|
US5959097A
(en)
*
|
1998-11-20 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of MEK2 expression
|
|
US5977341A
(en)
*
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
|
US5962673A
(en)
*
|
1998-11-20 |
1999-10-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-alpha expression
|
|
US5981732A
(en)
*
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
|
US20040171566A1
(en)
*
|
1999-04-06 |
2004-09-02 |
Monia Brett P. |
Antisense modulation of p38 mitogen activated protein kinase expression
|
|
JP2003515525A
(ja)
*
|
1999-04-06 |
2003-05-07 |
イースト カロライナ ユニバーシティ |
気管支収縮、肺炎、アレルギーおよびサーファクタント枯渇と関連する気道障害を治療するための、低アデノシンアンチセンスオリゴヌクレオチド、その組成物、キットならびにその方法
|
|
US6140124A
(en)
*
|
1999-04-06 |
2000-10-31 |
Isis Pharmaceuticals Inc. |
Antisense modulation of P38 mitogen activated protein kinase expression
|
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
|
US6013788A
(en)
*
|
1999-04-09 |
2000-01-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Smad3 expression
|
|
US6046321A
(en)
*
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
|
DE19935756A1
(de)
*
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
|
PT1200580E
(pt)
*
|
1999-08-13 |
2005-03-31 |
Hybridon Inc |
Modulacao da estimulacao imunitaria mediada por oligonucleotidos cpg atraves de modificacao posicional de nucleosidos
|
|
EP1496121A3
(en)
*
|
1999-08-13 |
2005-02-09 |
Hybridon, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
WO2001024820A1
(en)
*
|
1999-10-07 |
2001-04-12 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
CA2291367A1
(en)
*
|
1999-12-06 |
2001-06-06 |
Isabelle Henry |
Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
|
|
DE60131430T2
(de)
|
2000-01-14 |
2008-10-16 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
|
|
KR100848973B1
(ko)
|
2000-02-23 |
2008-07-30 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
종양 특이적 동물 단백질
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US20040006036A1
(en)
*
|
2000-04-12 |
2004-01-08 |
Gmr, A Delaware Corporation |
Silencing transcription by methylation
|
|
ES2305086T3
(es)
|
2000-05-19 |
2008-11-01 |
Corixa Corporation |
Tratamiento profilactico y terapeutico de enfermedades alergicas, autoinmunes e infecciosas con compuestos con base de monosacaridos.
|
|
EP2133100B1
(en)
*
|
2000-06-20 |
2011-10-05 |
Corixa Corporation |
MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
|
|
EP1319069B1
(en)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
CA2423487C
(en)
*
|
2000-09-26 |
2015-12-15 |
Hybridon, Inc. |
Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
|
|
WO2002069369A2
(en)
*
|
2000-12-08 |
2002-09-06 |
Coley Pharmaceutical Gmbh |
Cpg-like nucleic acids and methods of use thereof
|
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
|
US7105495B2
(en)
*
|
2001-04-30 |
2006-09-12 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
EP2423335B1
(en)
*
|
2001-06-21 |
2014-05-14 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same
|
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
|
WO2003020884A2
(en)
|
2001-08-14 |
2003-03-13 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
|
EP1567641B1
(en)
|
2001-08-24 |
2012-05-23 |
UVic Industry Partnerships Inc. |
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
|
|
MXPA04002631A
(es)
*
|
2001-09-20 |
2004-07-08 |
Glaxo Group Ltd |
Vacunas de adn optimizadas por codon gag-vih.
|
|
AU2002353783A1
(en)
|
2001-09-24 |
2003-04-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
|
|
US7514415B2
(en)
|
2002-08-01 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
|
|
WO2003035836A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
|
ATE554169T1
(de)
*
|
2001-11-02 |
2012-05-15 |
Giuliani Int Ltd |
Smad7-inhibitoren zur behandlung von krankheiten des zns
|
|
EP1581119B1
(en)
|
2001-12-17 |
2013-01-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
|
WO2003054161A2
(en)
|
2001-12-20 |
2003-07-03 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
|
EP1474432A1
(en)
*
|
2002-02-04 |
2004-11-10 |
Biomira Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
|
AU2003213118A1
(en)
|
2002-02-15 |
2003-09-09 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
RU2389732C2
(ru)
|
2003-01-06 |
2010-05-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
|
US7354907B2
(en)
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
|
EP1608403A2
(en)
*
|
2003-04-02 |
2005-12-28 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
|
CA2536139A1
(en)
|
2003-09-25 |
2005-04-07 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid-lipophilic conjugates
|
|
US8188254B2
(en)
*
|
2003-10-30 |
2012-05-29 |
Coley Pharmaceutical Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
|
WO2005115359A2
(en)
|
2004-05-06 |
2005-12-08 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the treatment of uveitis
|
|
CA2837748C
(en)
|
2004-05-25 |
2016-03-08 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
|
GB0427131D0
(en)
*
|
2004-12-10 |
2005-01-12 |
Glaxosmithkline Biolog Sa |
Novel combination
|
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
KR20070121814A
(ko)
|
2005-03-31 |
2007-12-27 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
클라미디아 감염에 대비한 백신
|
|
ES2524572T3
(es)
|
2005-04-29 |
2014-12-10 |
Glaxosmithkline Biologicals S.A. |
Procedimiento novedoso de prevención o tratamiento de infección por M. tuberculosis
|
|
KR101365538B1
(ko)
|
2005-06-14 |
2014-02-21 |
프로톡스 테라페유틱 인코포레이티드 |
변형된 포어 형성 단백질을 이용하여 양성 전립선 비대를치료하거나 예방하는 방법
|
|
MX2009003398A
(es)
|
2006-09-27 |
2009-08-12 |
Coley Pharm Gmbh |
Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
|
|
MX351247B
(es)
|
2007-04-04 |
2017-10-05 |
Infectious Disease Res Institute Star |
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
|
|
TW200908994A
(en)
|
2007-04-20 |
2009-03-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
WO2009006479A2
(en)
|
2007-07-02 |
2009-01-08 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
|
NZ585556A
(en)
|
2007-11-07 |
2012-07-27 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
|
PL2222710T3
(pl)
|
2007-12-24 |
2017-01-31 |
Id Biomedical Corporation Of Quebec |
Rekombinowane antygeny rsv
|
|
US8222225B2
(en)
|
2008-05-21 |
2012-07-17 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating pneumoconiosis with oligodeoxynucleotides
|
|
CA2745603A1
(en)
|
2008-12-03 |
2010-06-10 |
Proyecto De Biomedicina Cima, S.L. |
Use of phenol soluble modulins for the development of vaccines
|
|
PL2445526T3
(pl)
|
2009-06-24 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Rekombinowane antygeny rsv
|
|
MX2012000036A
(es)
|
2009-06-24 |
2012-02-28 |
Glaxosmithkline Biolog Sa |
Vacuna.
|
|
EP3178490B1
(en)
|
2009-07-15 |
2022-04-20 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
CN103154034B
(zh)
|
2010-04-13 |
2016-06-08 |
塞尔德克斯医疗公司 |
结合人cd27的抗体及其用途
|
|
US20130345079A1
(en)
|
2010-10-27 |
2013-12-26 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
|
BR112013011420A2
(pt)
|
2010-11-08 |
2016-08-02 |
Infectious Disease Res Inst |
vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
|
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
|
SI3275892T1
(sl)
|
2011-05-13 |
2020-06-30 |
Glaxosmithkline Biologicals S.A. |
Prefuzijski RSV F antigeni
|
|
EP2723365A1
(en)
|
2011-06-21 |
2014-04-30 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
|
PT2879701T
(pt)
|
2012-08-03 |
2024-02-12 |
Access To Advanced Health Inst |
Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
|
|
SG11201500573RA
(en)
|
2012-08-06 |
2015-02-27 |
Glaxosmithkline Biolog Sa |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
|
HRP20240996T1
(hr)
|
2013-03-13 |
2024-10-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefuzija rsv f proteina i njihova uporaba
|
|
EP3608332B1
(en)
|
2013-03-15 |
2022-06-01 |
GlaxoSmithKline Biologicals SA |
Vaccine against human rhinovirus
|
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
|
CA2919773A1
(en)
|
2013-08-05 |
2015-02-12 |
Glaxosmithkline Biologicals S.A. |
Combination immunogenic compositions
|
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
|
EP3154576A1
(en)
|
2014-06-13 |
2017-04-19 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic combinations
|
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
|
MA40920A
(fr)
|
2014-11-07 |
2017-09-12 |
Takeda Vaccines Inc |
Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
|
|
DK3233912T3
(da)
|
2014-12-19 |
2021-08-02 |
Regenesance B V |
Antistoffer, der binder human c6, og anvendelser deraf
|
|
WO2016112195A1
(en)
|
2015-01-09 |
2016-07-14 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
WO2016140702A1
(en)
|
2015-03-03 |
2016-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces |
Display platform from bacterial spore coat proteins
|
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
CA2986961C
(en)
|
2015-05-26 |
2023-07-25 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
|
GB2542425A
(en)
|
2015-09-21 |
2017-03-22 |
Mologen Ag |
Means for the treatment of HIV
|
|
WO2017184619A2
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
WO2017205225A2
(en)
|
2016-05-21 |
2017-11-30 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
|
EP3463440A4
(en)
|
2016-05-27 |
2020-04-15 |
Etubics Corporation |
NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
|
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
|
US11084850B2
(en)
|
2016-12-16 |
2021-08-10 |
The Pirbright Institute |
Recombinant prefusion RSV F proteins and uses thereof
|
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
UA129243C2
(uk)
|
2017-04-19 |
2025-02-26 |
Інстітьют Фо Рісьорч Ін Біомедцін |
Антитіло, що зв'язується зі спорозоїтами p. falciparum
|
|
KR20240096685A
(ko)
|
2017-06-15 |
2024-06-26 |
액세스 투 어드밴스드 헬스 인스티튜트 |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
|
CN111615397B
(zh)
|
2017-11-03 |
2024-09-13 |
武田疫苗股份有限公司 |
寨卡疫苗和免疫原性组合物及其使用方法
|
|
WO2019147925A1
(en)
|
2018-01-26 |
2019-08-01 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
CN112166118B
(zh)
|
2018-03-22 |
2025-07-11 |
德克萨斯大学体系董事会 |
治疗自身免疫性疾病和癌症的可溶性白介素-7受体(sIL7R)调节疗法
|
|
SG11202010011RA
(en)
|
2018-04-17 |
2020-11-27 |
Celldex Therapeutics Inc |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
|
AU2021337493A1
(en)
|
2020-09-04 |
2023-05-18 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
|
MX2023011788A
(es)
|
2021-04-09 |
2023-10-11 |
Celldex Therapeutics Inc |
Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
|
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
|
IL319329A
(en)
|
2022-09-09 |
2025-05-01 |
Access To Advanced Health Inst |
Immunogenic vaccine composition incorporating saponin
|
|
CN121219315A
(zh)
|
2023-03-03 |
2025-12-26 |
塞德斯医疗公司 |
抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体
|